Cargando…
The Severe Asthma Questionnaire: sensitivity to change and minimal clinically important difference
The Severe Asthma Questionnaire (SAQ) is sensitive to change and clinically significant improvement was detected within 4 weeks of starting biologic therapy. The MCID of the SAQ is 0.5 and of the SAQ-global is 11. https://bit.ly/3poJqcG
Autores principales: | Masoli, Matthew, Lanario, Joseph W., Hyland, Michael E., Menzies-Gow, Andrew, Mansur, Adel H., Allen, David, Dodd, James W., Hayes, Gemma, Valderas, Jose M., Lamb, Sarah E., Jones, Rupert C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209483/ https://www.ncbi.nlm.nih.gov/pubmed/33632801 http://dx.doi.org/10.1183/13993003.00300-2021 |
Ejemplares similares
-
Validation of subscales of the Severe Asthma Questionnaire (SAQ) using exploratory factor analysis (EFA)
por: Lanario, Joseph W., et al.
Publicado: (2020) -
Comparison of the sensitivity of patient-reported outcomes for detecting the benefit of biologics in severe asthma
por: Hyland, Michael E, et al.
Publicado: (2021) -
The construction and validation of the Severe Asthma Questionnaire
por: Hyland, Michael E., et al.
Publicado: (2018) -
How patient participation was used to develop a questionnaire that is fit for purpose for assessing quality of life in severe asthma
por: Hyland, Michael E., et al.
Publicado: (2018) -
The impact of asthma on mental health and wellbeing during COVID-19 lockdown
por: Higbee, Daniel H., et al.
Publicado: (2021)